SynthesisPloS one2020
A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment.
Synthesis in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Features and results availability of non-commercial Spanish COVID-19 trials: a systematic review of clinical trial registers and corresponding literature.European journal of clinical pharmacology · 2025Pooled it
- Randomized controlled trials in patients with COVID-19: a systematic review and critical appraisal.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.Scientific reports · 2021Pooled it
- Prophylaxis for COVID-19: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Pooled it
- Pooled it
- Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial.Archives of medical research · 2022Trial
- Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial.PloS one · 2022Trial
- Dissemination of Registered COVID-19 Clinical Trials (DIRECCT): a cross-sectional study.BMC medicine · 2023Article
- COVID-19 vaccine registry for pregnant women: policy to control complications of vaccination in pregnant women in 2021-2022.BMC pregnancy and childbirth · 2023Article
- Estimating the effect of COVID-19 on trial design characteristics: a registered report.Royal Society open science · 2023Article
- An update of anti-viral treatment of COVID-19Turkish journal of medical sciences · 2021Review
- Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study.BMJ open · 2021Article
- A Review on the Role of Stem Cells against SARS-CoV-2 in Children and Pregnant Women.International journal of molecular sciences · 2021Review
- Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently?The Canadian journal of cardiology · 2021Review
- Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.Epilepsy research · 2021Review
- Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.Biomedicines · 2021Article
- SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics.Expert review of proteomics · 2021Review
- Systemic Inflammatory Index Is a Novel Predictor of Intubation Requirement and Mortality after SARS-CoV-2 Infection.Pathogens (Basel, Switzerland) · 2021Article
- Article
- Mesenchymal Stem Cells and COVID-19: Cure, Prevention, and Vaccination.Stem cells international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo identify investigated interventions for COVID-19 prevention or treatment via trial registry entries on planned or ongoing randomised clinical trials. To assess these registry entries for recruitment status, planned trial size, blinding and reporting of mortality.
methodsWe identified trial registry entries systematically via the WHO International Clinical Trials Registry Platform and 33 trial registries up to June 23, 2020. We included relevant trial registry entries for randomized clinical trials investigating medical preventive, adjunct or supportive therapies and therapeutics for treatment of COVID-19. Studies with non-random and single-arm design were excluded. Trial registry entries were screened by two authors independently and data were systematically extracted.
resultsWe included 1303 trial registry entries from 71 countries investigating 381 different single interventions. Blinding was planned in 47% of trials. Sample size was >200 participants in 40% of trials and a total of 611,364 participants were planned for inclusion. Mortality was listed as an outcome in 57% of trials. Recruitment was ongoing in 54% of trials and completed in 8%. Thirty-five percent were multicenter trials. The five most frequent investigational categories were immune modulating drugs (266 trials (20%)), unconventional medicine (167 trials (13%)), antimalarial drugs (118 trials (9%)), antiviral drugs (100 trials (8%)) and respiratory adjuncts (78 trials (6%)). The five most frequently tested uni-modal interventions were: chloroquine/hydroxychloroquine (113 trials with 199,841 participants); convalescent plasma (64 trials with 11,840 participants); stem cells (51 trials with 3,370 participants); tocilizumab (19 trials with 4,139 participants) and favipiravir (19 trials with 3,210 participants).
conclusionAn extraordinary number of randomized clinical trials investigating COVID-19 management have been initiated with a multitude of medical preventive, adjunctive and treatment modalities. Blinding will be used in only 47% of trials, which may have influence on future reported treatment effects. Fifty-seven percent of all trials will assess mortality as an outcome facilitating future meta-analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.